That sounds similar the prevailing criticism of biotech companies: their primary concern is to develop treatments for the rich or, at a very minimum, common (and often trivial) conditions in first world nations. In other words, for people who can afford to pay. The only real difference in the latter case is that wealthy nations are pulling the strings.
Yes, which is why we need to protect publicly-funded biomedical research—grant review tends to be more sober and less selfish than investment capital.
